AAV-vglut2-hM3D(Gq)-EGFP-WPREs

Research background

This AAV supports chemogenetic modulation of cellular signaling or excitability via engineered receptors. Chemogenetics is commonly used when longer-duration, less temporally precise modulation is desired compared with optogenetics.

Mechanism and expected readouts

Expression of the engineered receptor enables ligand-dependent control over downstream signaling. Typical considerations include ligand selection/dose, onset and washout kinetics, and potential off-target effects at high doses.

Expression design and interpretation

Expression is driven by the VGLUT2 promoter, which determines where and how strongly the payload is expressed in your system (glutamatergic neurons). The construct's regulatory logic controls where/when the payload is active; expression is constitutive (no recombinase or inducer required). A built-in reporter/tag supports validation and localization; EGFP provides a green fluorescent protein (Ex ~488 nm / Em ~507 nm) readout for expression, morphology, and targeting validation. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control). Chemogenetic receptors enable ligand-dependent modulation with minutes-to-hours time scales, often suitable for behavioral paradigms.

Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.

Common research applications

• Sustained activation or inhibition of defined cell populations
• Longer-timescale behavioral modulation (minutes to hours)
• Dissection of neuromodulatory pathways via receptor-specific signaling

Experimental considerations

• Use vehicle controls and dose-response designs when possible
• Allow adequate time for ligand onset and washout in your behavioral schedule
• Validate expression/function in a subset of animals or cultures before scaling up

Controls and validation

Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.

• Sales Terms and Conditions (PDF)
• SDS (PDF)

At present, the main purification approaches for rAAV include:

• Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
• Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
• Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.